Atopic Dermatitis

A post-hoc analysis of phase 3 trials found tapinarof cream 1% produced skin clearance and itch relief as early as week 1 in patients aged 2 years and older.

This release by Apogee Therapeutics highlights findings from the phase 2 APEX trial on zumilokibart (APG777) in adults with moderate to severe atopic dermatitis.

Following the release of new results from the phase 3 ADorable-1 trial on lebrikizumab in pediatric patients, Amy Paller, MD, speaks in a new Q&A interview.

Allergy experts weigh ruxolitinib, tapinarof, and roflumilast—new nonsteroidal creams that reshape atopic dermatitis care beyond steroids.

This interview highlights key points regarding new data on roflumilast cream 0.05% in children aged 2 to 5 years with atopic dermatitis.

Lebrikizumab posts strong Phase 3 gains in infants to teens with atopic dermatitis, supporting FDA label expansion and itch relief.

These data, resulting from the INTEGUMENT-OLE trial, highlight the efficacy and safety of roflumilast cream (ZORYVE) 0.05% in children aged 2 - 5 years.

Twice-daily delgocitinib cream 20 mg/g in those with moderate to severe chronic hand eczema led to significant HRQoL improvements.

Once-daily VTAMZA delivers week-one sleep gains and lasting itch control in atopic dermatitis, with safety consistent across studies.

Post hoc pooled data from ADORING 1 and 2 demonstrate statistically significant improvements in patient and family sleep scores in children aged 2–17 years

This Q&A summarizes a recent 2026 Maui Derm Hawaii interview with Walter J. Liszewski, MD, regarding contact dermatitis updates.

These data highlight the impact of rezpegaldesleukin therapy on adults with moderate-to-severe atopic dermatitis in the phase 2b REZOLVE-AD study.

An interview conducted at Maui Derm 2026 highlights a presentation by Raj Chovatiya, MD, PhD, on managing atopic dermatitis and itch in 2026.

Investigators assessed the efficacy of switching to upadacitinib in those with atopic dermatitis who had an inadequate response to dupilumab.

This segment of Liszewski’s interview at Maui Derm Hawaii 2026 highlights additional takeaways for clinicians regarding the treatment of contact dermatitis.

In this Maui Derm Hawaii 2026 interview, key takeaways on contact dermatitis treatment strategies are highlighted by Liszewski.

Recent pooled analysis data suggest consistently low adverse event rates with upadacitinib over 7 years for patients with atopic dermatitis.

These new phase 2 INTEGUMENT-INFANT study findings point to the efficacy and safety of roflumilast cream 0.05% (Zoryve) in infants with eczema.

At the Maui Derm Hawaii 2026 conference, Lawrence Eichenfield, MD, spoke about highlights from his talk, ‘Atopic Dermatitis and Pruritus: Current Concepts and Therapeutics for 2026.’

However, key secondary endpoints, including measures of erythema, were not met in all analyses.

In these new phase 3b/4 data from LEVEL UP, findings on switching from dupilumab to upadacitinib in patients with atopic dermatitis are explored.

A smartphone-based patient-caregiver educational program was evaluated in its impact on relapse rates in children with moderate-to-severe atopic dermatitis.

Once-daily treatment of atopic dermatitis with oral ICP-332 showed a favorable safety profile and meaningful efficacy in a new study.

Both ethnicity and skin phototype were found in this analysis not to independently influence patients’ level of atopic dermatitis severity or their quality of life (QoL).

Investigators ranked the short-term effectiveness of 4 oral JAKis, upadacitinib, abrocitinib, baricitinib, and ivarmacitinib in moderate-to-severe atopic dermatitis.